Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity

Abstract Lung cancers bearing oncogenic EML4-ALK fusions respond to targeted tyrosine kinase inhibitors (TKIs; e.g., alectinib), with variation in the degree of shrinkage and duration of treatment (DOT). However, factors that control this response are not well understood. While the contribution of t...

Full description

Bibliographic Details
Main Authors: Emily K. Kleczko, Trista K. Hinz, Teresa T. Nguyen, Natalia J. Gurule, Andre Navarro, Anh T. Le, Amber M. Johnson, Jeff Kwak, Diana I. Polhac, Eric T. Clambey, Mary Weiser-Evans, Daniel T. Merrick, Michael C. Yang, Tejas Patil, Erin L. Schenk, Lynn E. Heasley, Raphael A. Nemenoff
Format: Article
Language:English
Published: Nature Portfolio 2023-02-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-023-00355-2

Internet

https://doi.org/10.1038/s41698-023-00355-2

Similar Items